Werewolf Therapeutics Inc. is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts. Werewolf Therapeutics specializes in the field of conditionally activated biologics (CABs), which are designed to selectively target and destroy cancer cells while minimizing harm to healthy tissues.
Werewolf Therapeutics is dedicated to addressing the limitations of traditional cancer treatments by leveraging its proprietary platform technology. The company's CABs are engineered to activate within the tumor microenvironment, allowing for precise and targeted therapeutic effects. By selectively activating within the tumor, the CABs can enhance the therapeutic index and improve the safety and efficacy of cancer treatments.